Search

Your search keyword '"Sewuese E. Akuse"' showing total 4 results
Start Over Author "Sewuese E. Akuse"
4 results on '"Sewuese E. Akuse"'

1. First-in-Human Assessment of Gut Permeability in Crohn’s Disease Patients Using Fluorophore Technology

Author

Lori R. Holtz, B. Darren Nix, Sewuese E. Akuse, Carla Hall-Moore, Rodney D. Newberry, Matthew A. Ciorba, Parakkal Deepak, Maria Zulfiqar, Jeng-Jong Shieh, James R. Johnson, I. Rochelle Riley, and Richard B. Dorshow

Subjects
Crohn’s Disease, Dual Sugar Absorption Test, Fluorescence Tracer Agent, Intestinal Permeability, MB-102, Relmapirazin, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and Aims: The dual sugar absorption test as a classic measure of human intestinal permeability has limited clinical utility due to lengthy and cumbersome urine collection, assay variability, and long turnaround. We aimed to determine if the orally administered fluorophore MB-102 (relmapirazin) (molecular weight [MW] = 372) compares to lactulose (L) (MW = 342) and rhamnose (R) (MW = 164)-based dual sugar absorption test as a measure of gut permeability in people with a spectrum of permeability including those with Crohn’s disease (CD). Methods: We performed a single-center, randomized, open-label, crossover study comparing orally administered MB-102 (1.5 or 3.0 mg/kg) to L (1000 mg) and R (200 mg). Adults with active small bowel CD on magnetic resonance enterography (cases) and healthy adults (controls) were randomized to receive either MB-102 or L and R on study day 1, and the other tracer 3 to 7 days later. Urine was collected at baseline and 1, 2, 4, 6, 8, 10, and 12 hours after tracer ingestion to calculate the cumulative urinary percent excretion of MB-102 and L and R. Results: Nine cases and 10 controls completed the study without serious adverse events. Urinary recovery of administered MB-102 correlated with recovery of lactulose (r-squared = 0.83) for all participants. MB-102 urine recovery was also tracked with the L:R ratio urine recovery (r-squared = 0.57). In controls, the percentages of L and MB-102 recovered were similar within a narrow range, unlike in CD patients. Conclusion: This first-in-human study of an orally administered fluorophore to quantify gastrointestinal permeability in adults with CD demonstrates that MB-102 is well tolerated, and its recovery in urine mirrors that of percent L and the L:R ratio.

Published
2024
Full Text
View/download PDF

2. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

Author

Rebecca E Schriefer, Dana C. Perantie, Lynne M. Mitchell, Darren Nix, Alexander Carvidi, Gregory F. Wu, Suha Abushamma, Diana Paez, Lily E McMorrow, Alem Haile, Kimberly E. Taylor, Alfred H.J. Kim, Michael A. Paley, Niti Pawar, Sewuese E. Akuse, Shannon E Sides, Maté Gergely, Alia A El-Qunni, Baylee Kinnett, William Buchser, Michael K. Klebert, Matthew A. Ciorba, Salim Chahin, Wooseob Kim, Katherine Huang, Patricia P. Katz, Lianne S. Gensler, Ali H. Ellebedy, Mary C. Nakamura, Monica Yang, Mariel J. Liebeskind, Jonathan Graf, Sean P. J. Whelan, Zhuoming Liu, Mehrdad Matloubian, Mahima Thapa, Jane A. O’Halloran, Emanuel G Demissie, Parakkal Deepak, and Rachel M. Presti

Subjects
medicine.medical_specialty, medicine.medical_treatment, Medical and Health Sciences, Vaccine Related, Rare Diseases, Clinical Research, Prednisone, General & Internal Medicine, Internal medicine, Internal Medicine, medicine, Prospective cohort study, biology, business.industry, Prevention, Immunogenicity, Antibody titer, Immunosuppression, General Medicine, Vaccination, Emerging Infectious Diseases, 3.4 Vaccines, biology.protein, Immunization, Antibody, business, medicine.drug, Cohort study
Abstract

BackgroundPatients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity in immunosuppressed patients with CID is unclear.ObjectiveTo determine the immunogenicity of mRNA-based SARS-CoV-2 vaccines in patients with CID.DesignProspective observational cohort study.SettingTwo U.S. CID referral centers.ParticipantsVolunteer sample of adults with confirmed CID eligible for early COVID-19 vaccination, including hospital employees of any age and patients older than 65 years. Immunocompetent participants were recruited separately from hospital employees. All participants received 2 doses of mRNA vaccine against SARS-CoV-2 between 10 December 2020 and 20 March 2021. Participants were assessed within 2 weeks before vaccination and 20 days after final vaccination.MeasurementsAnti-SARS-CoV-2 spike (S) IgG+ binding in all participants, and neutralizing antibody titers and circulating S-specific plasmablasts in a subset to assess humoral response after vaccination.ResultsMost of the 133 participants with CID (88.7%) and all 53 immunocompetent participants developed antibodies in response to mRNA-based SARS-CoV-2 vaccination, although some with CID developed numerically lower titers of anti-S IgG. Anti-S IgG antibody titers after vaccination were lower in participants with CID receiving glucocorticoids (n=17) than in those not receiving them; the geometric mean of anti-S IgG antibodies was 357 (95% CI, 96 to 1324) for participants receiving prednisone versus 2190 (CI, 1598 to 3002) for those not receiving it. Anti-S IgG antibody titers were also lower in those receiving B-cell depletion therapy (BCDT) (n=10). Measures of immunogenicity differed numerically between those who were and those who were not receiving antimetabolites (n=48), tumor necrosis factor inhibitors (n=39), and Janus kinase inhibitors (n=11); however, 95% CIs were wide and overlapped. Neutralization titers seemed generally consistent with anti-S IgG results. Results were not adjusted for differences in baseline clinical factors, including other immunosuppressant therapies.LimitationsSmall sample that lacked demographic diversity, and residual confounding.ConclusionCompared with nonusers, patients with CID treated with glucocorticoids and BCDT seem to have lower SARS-CoV-2 vaccine-induced antibody responses. These preliminary findings require confirmation in a larger study.Primary funding sourceThe Leona M. and Harry B. Helmsley Charitable Trust, Marcus Program in Precision Medicine Innovation, National Center for Advancing Translational Sciences, and National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Published
2021

3. Su1481: IMPACT OF IMMUNOSUPPRESSIVE THERAPIES ON ANTIBODY DECAY FOLLOWING MRNA VACCINATION TO SARS-COV-2 IN A PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES

Author

Parakkal Deepak, Wooseob Kim, Michael Paley, Monica Yang, Samantha Burdess, Alexander B. Carvidi, Emanuel Demissie, Alia A. El-Qunni, Alem Haile, Katherine Huang, Guadalupe Oliva Escudero, Lily E. McMorrow, Diana Paez, Niti Pawar, Dana C. Perantie, Rebecca E. Schriefer, Shannon E. Sides, Mahima Thapa, Maté Gergely, Sewuese E. Akuse, Michael Klebert, Lynne Mitchell, Billy D. Nix, Jonathan Graf, Kimberly E. Taylor, Salim Chahin, Matthew A. Ciorba, Patricia Katz, Mehrdad Matloubian, Jane A. O'Halloran, Rachel M. Presti, Gregory F. Wu, Lianne S. Gensler, Mary C. Nakamura, Ali H. Ellebedy, and Alfred H. Kim

Subjects
Hepatology, Gastroenterology
Published
2022

4. Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN'S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES

Author

Jeng J. Shieh, Lori R. Holtz, Richard B. Dorshow, Rodney D. Newberry, Sewuese E. Akuse, Carla Hall-Moore, I.R. Riley, Parakkal Deepak, James R. Johnson, Billy D. Nix, and Matthew A. Ciorba

Subjects
Crohn's disease, Pathology, medicine.medical_specialty, Intestinal permeability, Hepatology, Pyrazine, Chemistry, Non invasive, Gastroenterology, medicine.disease, chemistry.chemical_compound, Human gut, medicine, Barrier integrity
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results